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To determine the optimal level of vaccination coverage defined as the level that minimizes
total costs and explore how economic results change with marginal changes to this level of
coverage.
Methods
A susceptible-infected-recovered-vaccinated model designed to represent theoretical infec-
tious diseases was created to simulate disease spread. Parameter inputs were defined to
include ranges that could represent a variety of possible vaccine-preventable conditions.
Costs included vaccine costs and disease costs. Health benefits were quantified as mone-
tized quality adjusted life years lost from disease. Primary outcomes were the number of
infected people and the total costs of vaccination. Optimization methods were used to deter-
mine population vaccination coverage that achieved a minimum cost given disease and
vaccine characteristics. Sensitivity analyses explored the effects of changes in reproductive
rates, costs and vaccine efficacies on primary outcomes. Further analysis examined the
additional cost incurred if the optimal coverage levels were not achieved.
Results
Results indicate that the relationship between vaccine and disease cost is the main driver of the
optimal vaccination level. Under a wide range of assumptions, vaccination beyond the optimal
level is less expensive compared to vaccination below the optimal level. This observation did
not hold when the cost of the vaccine cost becomes approximately equal to the cost of disease.
Discussion and Conclusion
These results suggest that vaccination below the optimal level of coverage is more costly
than vaccinating beyond the optimal level. This work helps provide information for assess-
ing the impact of changes in vaccination coverage at a societal level.
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Introduction
Vaccines provide a benefit to society by preventing disease and controlling the spread of dis-
ease in the population [1]. However, vaccination programs also require large investments [2].
As costs of newer vaccines increase, understanding and determining the relative value of vari-
ous vaccination programs is becoming increasingly important [3]. Because some vaccination
programs may be competing for the same set of resources, funding one vaccine could come at
the expense of another. Vaccinating too few individuals risks higher costs of disease whereas
vaccinating too many risks spending too much on things like education, targeting, administra-
tion, and vaccine doses. Given the competing interests of societal benefit and high cost of
implementation, it is important to identify the optimal level of vaccination coverage for a dis-
ease in order to avoid the costs of over- or under-vaccination and to help prioritize efforts to
increase vaccination coverage [2, 4–6].
There are two common approaches to optimizing vaccination coverage levels. The first is to
determine the level of vaccination coverage required to reduce the reproductive rate of the dis-
ease (R0) to 1. Reducing the R0 to 1, achieves indirect effects and stops the spread of disease in
a population [5, 7–9]. The other approach is to minimize the total costs of vaccination [4, 6] by
varying levels of vaccination coverage. The objective of this research was to examine the opti-
mal population vaccination coverage levels for a variety of disease and vaccine characteristics
to investigate the effect on costs given sub-optimal vaccination coverage.
Methods
The classic epidemic Susceptible–Infected–Recovered (SIR) model was modified with vaccina-
tion included as a fourth model state [10]. For simplicity, all diseases were assumed to be non-
fatal, and vaccination was assumed to provide permanent protection against disease. The
model is described by the following series of differential Eqs 1–4.
dS=dt ¼ lS ð1Þ
dI=dt ¼ lS gI ð2Þ
dR=dt ¼ gI ð3Þ
dV=dt ¼ 0 ð4Þ
Eqs 1–4. Equation set for SIRV model: Notes: S: Susceptible. I: Infected. R: Recovered. V:
Vaccinated. λ: Force of Infection = (βI/N). β: Transmission Rate from Susceptible to Infected =
(γR0). γ: Recovery Rate = (1 / infection period (days)). R0: Reproductive Rate. N: Total popu-
lation size.
General parameters that could be representative of a wide range of vaccine-preventable con-
ditions were used; Table 1 provides a list of parameter inputs for the SIRV model.
The model was seeded with one infected individual and a population of 1,000,000 that were
split between susceptible and effectively vaccinated depending on the vaccine coverage and effi-
cacy. Vaccination coverage was varied from 0 to 100% to provide data for determining the pop-
ulation vaccination coverage to achieve the minimum total cost; hereafter the optimal
vaccination level. Vaccine efficacy is defined as the fraction of individuals being fully-protected
by the vaccine. Those not fully-protected were assumed to be completely susceptible. Each
model was run over a two-year time horizon. Two-years was selected as it provided enough
time to complete one full outbreak of the disease for each R0 and infection period tested. The
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model was constructed using the statistical software R (version 3.2.3). The model predicted the
following set of outcomes for each run: the remaining number of people susceptible to disease
and the number of people either still infected or recovered from disease after the two-year time
horizon.
Optimal Vaccination Level Analysis
SIRV model outcomes were utilized to determine the optimal coverage and provide insights
into the value of incremental changes to coverage. The number of people vaccinated, along
with the number of people either still infected or recovered from disease were used to explore
the relationship between the cost of disease and cost of vaccination and how this relationship
alters the optimal vaccination level. The main outcomes of interest in all analyses were the total
cost and the associated optimal vaccination level.
Eq 5 shows total cost (TC) for any level of vaccination coverage. TC was constructed using
results of the SIRV model, parameters for disease costs and a disease to vaccine cost ratio
(DVCR). The cost of disease combines three components: 1) Dollar cost of disease; 2) Quality
adjusted life years (QALYs) lost due to disease; 3) Willingness-to-pay (WTP) per QALY. To
examine a variety of possibilities for the utility lost due to disease, a range of possible QALY
losses were selected. As there is no currently accepted threshold for a WTP per QALY in the
US [11], several different WTP values were tested to encompass the plausible ranges for the
societal WTP for QALYs lost. QALYs were monetized by multiplying the WTP per QALY and
the number of QALYs lost due to disease, as shown in Eq 5. The list of QALYs lost, and WTP
per QALY are provided in Table 2. Each component of the cost of disease was examined in
one-way sensitivity analysis to determine its effect on the optimal vaccine coverage.
TCx ¼ x  NSus  CostVacð Þ þ ðNRec þ NInf Þ  CostDis þ QALYs Lost 
WTP
QALY
   
ð5Þ
Eq 5. Total cost: NSus: Initial number of susceptible people. NRec: Number recovered from
infection after simulated outbreak epidemic (2 years). NInf:: Remaining number infected after
simulated outbreak (2 years). x: Level of vaccination coverage (%). CostDis: Disease cost ($).
CostVac: Cost of vaccine ($). Subject to disease dynamics Eqs 1–4.
Table 2. Model inputs for optimal vaccination level analysis.
Variable Base-case Other values
Disease cost per person ($) 1000 10, 100, 2000, 2500, 5000, 10000
QALYs lost per person 0.005 0.0001, 0.001, 0.01, 0.025, 0.05, 0.1, 0.5, 1
Willingness to pay per QALY ($) 100000 25000–250000, by 25000
Disease to vaccine cost ratio (DVCR) 15 1, 2, 3, 4, 5, 10,15, 20, 25, 50, 75, 100, 1000, 10000
doi:10.1371/journal.pone.0156737.t002
Table 1. Model inputs and ranges for SIRVmodel.
Disease and vaccination parameters Values
Total population size, N 1000001
Reproductive Rate (R0) 1.1–10.0
Infection period (days) 7, 14, 21, 42
Recovery Rate (γ) (0.02–0.14)
Transmission Rate from Susceptible to Infected (β) (0.03–1.4)
Vaccine efficacy (%) 80–100
doi:10.1371/journal.pone.0156737.t001
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Once the parameters for disease cost were selected, disease cost was assumed to be fixed for
each analysis. The cost of the vaccine was determined by altering the DVCR. As disease cost
was fixed, it is important to note that altering this ratio is indicative of change in the vaccine
cost not the disease cost. An increase in DVCR thus implies a reduction in the cost of the vac-
cine. The range of the DVCR is provided in Table 2.
Eq 5 demonstrates there is a total cost (TCx) for each level of population vaccination cover-
age (x). The optimal vaccination level is defined as the minimum possible total cost when vac-





Eq 6. Optimal vaccination level: x: Level of vaccination coverage (%). TC: Total cost as
defined in Eq 5. 0 x 100. Subject to disease dynamics Eqs 1–4.
Total Costs of Over- and Under-Vaccination
To compare the cost of under-vaccinating (i.e., achieving a vaccination coverage lower than the
optimal level) to over-vaccinating (i.e., achieving a vaccination coverage higher than the opti-
mal level), we created a metric of the excess cost above the minimum, defined by Eq 7. The
symmetry or asymmetry in the costs of vaccinating at levels less than and greater than the opti-
mal level was examined.
yðxÞ ¼ TCx  TCx ð7Þ
Eq 7. Excess cost above minimum: y(x): Difference from the minimum total cost at vaccina-
tion percentage x. TCx: Total cost as defined in Eq 5. TCx: Minimum total cost as defined in
Eq 6. Subject to disease dynamics Eqs 1–4.
Optimal Vaccination Level and Indirect Effects
The economically optimal vaccination coverage level, x, as defined by minimizing TCmay be
different from the epidemiologic minimum level of vaccination coverage, z, where indirect
effects lead to a decline in the incidence of infection (“herd immunity threshold”)(shown by Eq
8). To study the relationship between these two values of vaccination coverage, we used a bisec-
tion search algorithm to determine the approximate DVCR at which the economically-optimal
vaccination coverage level, x, is equivalent to the indirect effects threshold, z, for various R0s
between 1.1 and 10.0.






Eq 8. Indirect Effects Threshold: z: Level of vaccination coverage (%). R0: Reproductive Rate
Results
Sensitivity analysis reveals that the optimal coverage level is robust to changes in the individual
components of disease cost. Fig 1 provides an example of the result from the one-way sensitiv-
ity analysis where the components of disease cost are presented at different values and DVCR
is held constant. Fig 1 shows the additional costs of sub-optimal vaccination coverage at a pop-
ulation level. The minimum point on Fig 1 indicates the optimal vaccination coverage (TCx)
for this combination of disease and vaccine characteristics. Results show that the optimal vacci-
nation coverage does not change when the individual components of disease cost are changed.
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Fig 1. Sensitivity analysis results. R0: 3.5, DVCR: 15. Values for parameters that remained constant during
one-way analysis: Direct costs: $10000. QALYs Lost: 0.05. WTP: $100000. (A) One-way sensitivity analysis
direct costs of disease. (B) One-way sensitivity analysis on QALYs lost due to disease. (C) One-way
sensitivity analysis on number WTP per QALY.
doi:10.1371/journal.pone.0156737.g001
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What does change is the additional cost due to not achieving the optimal coverage level. That
is, from an optimization perspective, the optimal coverage level is not sensitive to components
of the cost of disease or the cost of the vaccine. Rather, it is driven by the DVCR.
Total Costs of Over- and Under-Vaccination
Fig 2 provides an example of the symmetry of excess costs near optimal coverage levels. Results
indicate that small deviations from optimal coverage can greatly impact additional costs. Not
surprisingly, as the cost of a vaccine drops (DVCR increases), the optimal level of population
vaccination coverage increases. Fig 2 shows that in this example; as DVCR varies over several
orders of magnitude, the optimal vaccination coverage (the horizontal position where the
graph line is minimized) may vary by a few percentage points. Under nearly all conditions,
missing the optimal coverage level by vaccinating a larger fraction of the population will result
in lower excess costs than missing the optimal coverage level by vaccinating a smaller fraction
of the population. The only instance when vaccination beyond the optimal coverage level can
be more expensive is when the disease and vaccine have the same cost (i.e., DVCR = 1.0).
Optimal Vaccination Level and Indirect Effects
Fig 3 shows how the economically-optimal vaccination percentage, x, compares to the level of
vaccination coverage, z, required to achieve indirect effects. The solid line in Fig 3 indicates the
DVCR at which the economically-optimal vaccination coverage, x, as defined by TCx , is
approximately equivalent to the population coverage, z, needed to achieve the indirect effects
threshold (z ± 0.01 (percentage points), for a particular R0. Results show that given disease and
vaccine characteristics and costs, there may be scenarios when the economically-optimal vacci-
nation percentage, x, is less or greater than the indirect effect threshold, z. Fig 3 indicates that if
the DVCR is sufficiently high and the disease is highly transmissible, it may be optimal to vac-
cinate beyond the point of indirect effects (i.e., the optimal may be above the black line). Con-
versely, if the DVCR is low (vaccine is expensive relative to disease) and the disease is not
highly transmissible, it may be economically-optimal to vaccinate below the indirect effects
threshold (i.e., the optimal may be below the black line).
Policy Example
One example of a policy recommendation generated from these results could be setting the tar-
get vaccination coverage level as little as two percentage points above the optimal level to help
Fig 2. Costs of vaccinating short of and beyond optimal levels.R0: 3.5. Vaccine Efficacy: 100%. Total
Disease Cost: $1,500.
doi:10.1371/journal.pone.0156737.g002
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minimize total expenditures. Fig 4 provides a visualization of this policy. If a vaccination target
is set at the optimal level and not achieved exactly, excess costs will be incurred. If the vaccina-
tion target is set at the optimal level and missed on the under-vaccination side by a small mar-
gin excess costs could be extremely high (e.g., ~ $100,000,000 for a population of 1 million
people). Conversely, if the target coverage level is set above the optimal and missed by the same
margin costs are much less burdensome (e.g.,< $10,000,000 for a population of 1 million
people).
Fig 3. DVCR and the relationship between the economically-optimal population coverage level and the indirect effects threshold. γ = 14
days. Solid line: Approximate DVCR where the economically-optimal vaccination level equals indirect effects threshold for a particular R0. Dashed
line: Economically-optimal coverage levels + 0.5 percentage points from indirect effects threshold. Dotted line: Economically-optimal coverage
levels– 0.5 percentage points from the indirect effects threshold.
doi:10.1371/journal.pone.0156737.g003
Fig 4. Policy example. R0: 5.0. Vaccine Efficacy: 95%. DVCR: 25. Disease Cost $1500. Dotted Line: Target
coverage level. Shaded region: ± 0–2 percentage point from target coverage level. (A) Target coverage at
optimal coverage level. (B) Target coverage level two percentage points above the optimal.
doi:10.1371/journal.pone.0156737.g004
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Discussion
The objective of this research was to examine the optimal population vaccination coverage lev-
els by identifying the minimum total costs for a variety of disease and vaccine characteristics,
and to use this information to gain insights to the costs and benefits as vaccination coverage
changes incrementally. Under reasonable conditions (i.e., the vaccine being less expensive than
the disease it protects against), results indicate there are much higher costs to vaccinating at
levels less than the optimal coverage level compared to vaccinating at levels greater than the
optimal. Although several papers provide examples for coverage optimization using similar or
other model structures [2, 4, 5, 12, 13], this paper adds to the optimization coverage literature
in some important ways. First, to our knowledge, this is the first paper that examines the
change in symmetry in over- and under-vaccination near optimal levels of coverage. A key
insight from this paper is the additional margin that exists by exceeding the optimal coverage
level and the possible policy implications. To some extent, the idea of additional margin
beyond optimal coverage is intuitive, however the rapid rate of change in additional expendi-
tures is difficult to capture without visualization. Also, understanding changes in symmetry for
different vaccines could aid priority setting for promotion of increased coverage for different
vaccines.
Mass vaccination is complicated and requires many processes to work simultaneously, and
many things can prevent a target coverage level from being obtained. For example, people may
cancel appointments or not show; vaccines may expire before being used; or people may opt
out of vaccination for religious, political, or social reasons. These and other reasons would con-
tribute to target coverage not being achieved; with coverage rates likely falling left of (lower
than) a set target. Contrary, for a vaccination target to be surpassed, many processes would
need to work better than planned. Therefore, in examining policy recommendations such as
the example from Fig 4, a strategy that employs vaccination beyond the optimal level as the tar-
get may be useful for minimizing costs as missing on the left side of the target could even lower
net costs, especially if the vaccine is inexpensive compared to disease.
If the indirect effects threshold is low, such is the case when the R0 is small, additional com-
plications may arise from policy considerations that would suggest that it is optimal to vacci-
nate near this threshold.
The methods used to find the optimal as well as providing a graphical example of the sym-
metry could be useful for priority setting for different vaccines. For example, if the optimal cov-
erage level for vaccine A is 90% and actual population coverage is at 95%, while the optimal
coverage for vaccine B is 80% but actual coverage of vaccine B is 60%, this might suggest that
resources be reallocated from promoting vaccine A to promoting vaccine B. How a regulatory
body could effectively communicate and equitably implement a policy is beyond the scope of
this paper; we do acknowledge that using only results from this type of model may provide
extra additional difficulties for decision makers. However, this model and its methods are use-
ful in situations where full coverage has not been achieved or where prioritization may be
required. Regardless, it is important to acknowledge that model results like this are only one
type of evidence considered when making vaccination policy or recommendations.
Because the aim of this study was to explore the potential impact of changes in coverage for
application to a wide range of vaccine-preventable conditions, the classic epidemic model was
chosen as it can reflect a range of disease conditions being considered. The classic epidemic
model illustrates how diseases progress through a population, easily allows us to track the
course of a hypothetical disease, and can provide insights for a wide variety of diseases as most
infectious diseases follow some variation of the susceptible-infected-recovered process.
Although we chose this simplified model instead of a more complicated disease-specific model
Optimal Vaccination Coverage and Risks of Error
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(with additional details that may have obscured the key insights), we see these methods as
something that could be readily adapted for dynamic transmission models of specific diseases.
There are some limitations with these models. First, our model assumes homogeneous pop-
ulation mixing. While assumption holds for some diseases, it would be important to account
for population heterogeneity for other diseases. Second, there is no age structure in these mod-
els. Accounting for the age structure of the population can help better account for associated
costs and vaccination coverage needs. Models with age structure could also evaluate the bene-
fits of expanding childhood vaccination for vaccines with lifelong protection. However, these
results could account for age groups if one assumes that the models are applicable to only a sin-
gle group of interest. Therefore, instead of the model representing people of all ages, the model
would represent a population where every person is a child or an adult. Third, assumptions for
vaccination and disease outcomes vary by condition. For example, people both vaccinated and
unvaccinated lose immunity over time for some diseases. Accounting for vaccination immu-
nity and natural immunity loss could play an important role in the total cost of vaccination.
Fourth, models were closed cohort. As the population changes (i.e., people being born, and
people dying) those entering the model would need to be vaccinated to keep coverage constant.
Although including these extra details of the models would provide extra accuracy for different
diseases, accounting for all of these additional pieces, would make the model structure much
more complex and would make it less generalizable. This paper also serves as a possible method
that could be readily applied to existing dynamic transmission models. Examining more com-
plex models and previously constructed dynamic transmission models using these methods is
an area for continuing research.
Costs are a possible limitation of this paper. The cost of the vaccine is a combination of
the vaccine itself as well as the administration cost; we acknowledge that administration
costs are likely to be dynamic given the vaccine and the level of coverage. Additionally, con-
sidering the impact of economies of scale could be important for events like childhood vacci-
nation (where many vaccines are received at one time) or the impact when multiple doses
are required to complete a vaccination schedule. However, as we find that only parameter
that impacts our results is DVCR, this ratio could certainty account for both vaccine and
administration costs, as well as multiple doses, and economies of scale. A further consider-
ation of cost would be the impact of symptomatic versus asymptotic transmission. In our
model we assume that the cost of disease is the average cost of disease across a population
which includes both asymptomatic and symptomatic transition. Therefore, the DVCR will
change as the percentage of symptomatic versus asymptomatic cases changes. Additional
work would be required for specific diseases to accurately calculate the total cost of vaccina-
tion, accounting for both direct and indirect costs, and the cost of disease, accounting for
symptomatic or asymptomatic transmission.
Conclusion
In summary, we have evaluated the optimal level of vaccination coverage considering the popu-
lation costs and benefits. Results suggest that vaccination at levels below the optimal is costlier
than vaccination at levels beyond the optimal when vaccination costs less than the disease.
Equipping decision makers with the knowledge that it is possible to over-vaccinate beyond the
optimal by small margins and only incur minimal additional costs is valuable. Further research
could examine more complex models, specific vaccines, and specific diseases to determine how
generalizable these results are. If results prove to be generalizable they could be used to help
inform practice and policy decisions or set target recommendations when mass vaccination
may be required.
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